Xenon Pharmaceuticals Inc (XENE) FinancialsXENEXenon Pharmaceuticals Inc

Evaluating the bottom line, Xenon Pharmaceuticals Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -43.62%, provide a clear picture of how effectively XENE converts its operational activities into shareholder value.

In the context of the broader market, XENE competes directly with industry leaders such as AMLX and IDYA. With a market capitalization of $3.77B, it holds a leading position in the sector. When comparing efficiency, XENE's gross margin of N/A stands against AMLX's N/A and IDYA's 100.00%. Such benchmarking helps identify whether Xenon Pharmaceuticals Inc. is trading at a premium or discount relative to its financial performance.

Xenon Pharmaceuticals has reported no revenue for multiple quarters, with a net loss of $110.7 million in Q2 2026. The gross margin is currently 0%, and the company has a forward P/E ratio of 0, indicating no expected earnings in the near term.